Compare FNWD & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FNWD | TLSA |
|---|---|---|
| Founded | 1994 | 2013 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 147.7M | 155.3M |
| IPO Year | 1996 | 2017 |
| Metric | FNWD | TLSA |
|---|---|---|
| Price | $36.51 | $0.98 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $37.50 | N/A |
| AVG Volume (30 Days) | 28.8K | ★ 199.2K |
| Earning Date | 04-28-2026 | 05-04-2026 |
| Dividend Yield | ★ 1.51% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.52 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $17.40 | N/A |
| Revenue Next Year | $5.44 | N/A |
| P/E Ratio | $70.43 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $26.70 | $0.99 |
| 52 Week High | $39.99 | $2.60 |
| Indicator | FNWD | TLSA |
|---|---|---|
| Relative Strength Index (RSI) | 62.65 | 36.47 |
| Support Level | $36.37 | N/A |
| Resistance Level | $38.86 | $1.45 |
| Average True Range (ATR) | 0.94 | 0.12 |
| MACD | -0.04 | -0.02 |
| Stochastic Oscillator | 33.66 | 17.78 |
Finward Bancorp is a bank holding company that engages in the provision of financial services. It offers products and services related to Personal Banking, Cash Management, Savings Account, ebanking, Wealth Management, and Insurance Services. It is engaged in the business of attracting deposits from the general public and the origination of loans, mostly upon the security of single-family residences and commercial real estate, construction loans, commercial business loans, and municipal loans. Geographically, the activities are carried out throughout the United States. The Company operates as a single reportable segment that derives its revenue mainly from the business of banking.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.